Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06211374 · ClinicalTrials.gov registry record · NA

Communication Bridge Pilot Study

A NA study of Primary Progressive Aphasia, sponsored by University of Chicago.

Active
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT06211374 is a NA study of Primary Progressive Aphasia that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 12 participants, below the 92-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06211374, a NA study of Primary Progressive Aphasia, is active but no longer recruiting, sponsored by University of Chicago.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to evaluate the effectiveness and feasibility of evidence-based interventions in individuals living with mild to moderate primary progressive aphasia (PPA) that address communication-focused outcomes.

Interventions

  • BEHAVIORAL Communication Bridge

Study Locations (1)

Illinois

  • University of Chicago - American School Building - Chicago

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-06-28
Est. Completion 2026-05-31
Phase NA

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT06211374

The ClinicalTrials.gov registry entry for NCT06211374 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (87% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 1 intervention - of which Communication Bridge is the first listed.

NCT06211374 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06211374 about?

NCT06211374 is a clinical study titled "Communication Bridge Pilot Study". The aim of this study is to evaluate the effectiveness and feasibility of evidence-based interventions in individuals living with mild to moderate primary progressive aphasia (PPA) that address communication-focused outcomes.

What is the current status of trial NCT06211374?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2024-06-28. Estimated completion is 2026-05-31.

What conditions does trial NCT06211374 study?

This clinical trial studies the following conditions: Primary Progressive Aphasia.

What interventions are being tested in trial NCT06211374?

The interventions under investigation include: Communication Bridge (BEHAVIORAL).

Who is sponsoring clinical trial NCT06211374?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06211374 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Progressive Aphasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.